Finafloxacin - CAS 209342-40-5
Category: APIs
Molecular Formula:
Molecular Weight:
Finafloxacin is a pH-activated fluoroquinolone antimicrobial agent indicated for the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
Related CAS:
209342-41-6 (hydrochloride)
White Solid
Xtoro; 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
Soluble in DMSO.
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -62℃ for long term (months to years).
Shelf Life:
2 years
Boiling Point:
686.2±55.0 °C at 760 mmHg
1.57±0.1 g/cm3
Canonical SMILES:
1.Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
Wagenlehner F;Nowicki M;Bentley C;Lückermann M;Wohlert S;Fischer C;Vente A;Naber K;Dalhoff A Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02317-17. doi: 10.1128/AAC.02317-17. Print 2018 Apr.
The broad-spectrum C-8-cyano-fluoroquinolone finafloxacin displays enhanced activity under acidic conditions. This phase II clinical study compared the efficacies and safeties of finafloxacin and ciprofloxacin in patients with complicated urinary tract infection and/or pyelonephritis. A 5-day regimen with 800 mg finafloxacin once a day (q.d.) (FINA05) had results similar to those of a 10-day regimen with 800 mg finafloxacin q.d. (FINA10). Combined microbiological and clinical responses at the test-of-cure (TOC) visit were 70% for FINA05, 68% for FINA10, and 57% for a 10-day ciprofloxacin regimen (CIPRO10) in 193 patients (64 for FINA05, 68 for FINA10, and 61 for CIPRO10) of the microbiological intent-to-treat (mITT) population. Additionally, the clinical effects of ciprofloxacin on patients with an acidic urine pH (80% of patients) were reduced, whereas the effects of finafloxacin were unchanged. Finafloxacin was safe and well tolerated. Overall, 43.4% of the patients in the FINA05 group, 42.7% in the FINA10 group, and 54.2% in the CIPRO10 group experienced mostly mild and treatment-emergent but unrelated adverse events. A short-course regimen of 5 days of finafloxacin resulted in high eradication and improved clinical outcome rates compared to those for treatment with ciprofloxacin for 10 days.
2.The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
Falagas ME;Mavroudis AD;Vardakas KZ Expert Rev Anti Infect Ther. 2016 Aug;14(8):747-63. doi: 10.1080/14787210.2016.1204911.
INTRODUCTION: ;A real concern in the medical community is the increasing resistance of bacteria, especially that of Gram-negative types. New antibiotics are currently under clinical development, promising to tackle severe infections caused, especially, by multi-drug resistant (MDR) bacteria and broaden the armamentarium of clinicians.;AREAS COVERED: ;We searched PUBMED and GOOGLE databases. Combinations of already approved β-lactams or monobactams with new β-lactamase inhibitors [imipenem-cilastatin/MK-7655 (relebactam), meropenem/RPX7009 (vaborbactam), ceftaroline/avibactam, aztreonam/avibactam], new β-lactams (S-649266, BAL30072), aminoglycosides (plazomicin), quinolones (finafloxacin) and tetracyclines (eravacycline) were included in the review. Expert commentary: For the majority of the upcoming antibiotics the currently available data is limited to their microbiology and pharmacokinetics. Their effectiveness and safety against infections due to MDR bacteria remain to be proved. Significant issues are also the impact of these antibiotics on the human intestinal microbiota and their possible co-administration with already-known antimicrobial agents in difficult-to-treat-infections; further studies should be conducted for these objectives.
3.Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.
Patel H;Andresen A;Vente A;Heilmann HD;Stubbings W;Seiberling M;Lopez-Lazaro L;Pokorny R;Labischinski H Antimicrob Agents Chemother. 2011 Sep;55(9):4386-93. doi: 10.1128/AAC.00832-10. Epub 2011 Jun 27.
Finafloxacin is a new fluoroquinolone antibiotic with the unique property of increasing antibacterial activity at pH values lower than neutral. Whereas its antibacterial activity at neutral pH matches that of other quinolones in clinical use, it is expected to surpass this activity in tissues and body fluids acidified by the infection or inflammation processes. Pharmacokinetic parameters of oral single and multiple doses of up to 800 mg of finafloxacin and safety/tolerability observations were assessed in a phase I study including 95 healthy volunteers. Finafloxacin is well absorbed after oral administration, generating maximum concentrations (C(max)s) in plasma at least comparable to those of other fluoroquinolones, with a half-life of around 10 h. About one-third of the dose is excreted unchanged in the urine. Renal elimination appears to be a saturable process leading to slight increases of the area under the concentration-time curve extrapolated to infinity and dose normalized (AUC(∞,norm)) at dosages of 400 mg and above. Safety and tolerability data characterize finafloxacin as a drug with a favorable safety profile. In particular, adverse reactions regarded as class-typical of fluoroquinolones, such as, e.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 126784-99-4 Ulipristal Acetate

Ulipristal Acetate
(CAS: 126784-99-4)

Ulipristal Acetate is an orally bioactive and selective progesterone receptor modulator (SPRM) used for emergency contraception and uterine fibroid. It binds to...

CAS 388082-77-7 Lapatinib ditosylate

Lapatinib ditosylate
(CAS: 388082-77-7)

CAS 2066-89-9 Pasiniazid

(CAS: 2066-89-9)

Pasiniazid, aslo alled as Fintosid, can be used to treat pulmonary tuberculosis (MDR-TB) and leprosy.

CAS 102767-28-2 Levetiracetam

(CAS: 102767-28-2)

CAS 1134-47-0 Baclofen

(CAS: 1134-47-0)

CAS 59277-89-3 Aciclovir

(CAS: 59277-89-3)

CAS 83919-23-7 Mometasone Furoate

Mometasone Furoate
(CAS: 83919-23-7)

CAS 183321-74-6 Erlotinib

(CAS: 183321-74-6)

Quick Inquiry

Verification code

Featured Items